Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




J. Craig Venter Keynote Speaker at International Biotechnology Convention

By Biotechdaily staff writers
Posted on 19 May 2008
The Biotechnology Industry Organization (BIO; Washington, DC, USA) announced the addition of J. More...
Craig Venter, Ph.D. to the 2008 BIO International Convention keynote speaker lineup.

The global event for biotechnology will take place June 17-20, 2008, at the San Diego Convention Center in San Diego, CA, USA. "We are excited and honored to have Dr. Venter at the 2008 BIO International Convention to share with us his insights and experience as one of the leading scientists of the 21st century,” said Jim Greenwood, president and CEO of BIO. "His pioneering research in genomics and alternative energy sources is making a tremendous impact on our industry.”

Dr. Venter's presentation, From Reading to Writing the Genetic Code,” will highlight the ways in which his early successes in genomics are now being used to lead the way toward developments in advanced biofuels through his cutting-edge use of tools and techniques in synthetic genomic research. Dr. Venter will explore how this innovative scientific research will benefit society and the biotechnology industry, as well as create unlimited new frontiers to explore in the areas of biofuels, environmental protection, and healthcare.

Dr. Venter is founder and president of the J. Craig Venter Institute, a not-for-profit, research organization with more than 400 scientists and staff dedicated to human, microbial, plant, synthetic, and environmental genomic research, as well as to the exploration of social and ethical issues in genomics. The institute is located in Rockville, MD, USA, and in La Jolla, CA, USA. Dr. Venter is also founder and president of Synthetic Genomics Inc., a privately held company developing and commercializing genomic-driven solutions to address global energy and environmental challenges.

In 1998, Dr. Venter founded Celera Genomics to sequence the human genome, using the whole-genome shotgun technique, new mathematical algorithms, and automated DNA-sequencing machines. The successful completion of this research culminated in the publication of the human genome in February 2001. He and his team at the Venter Institute continued this work and published the first complete diploid genome in 2007.

The BIO International Convention will highlight how biotechnology, the life sciences, investments, policy, and the international community work together to heal, fuel, and feed the world. The BIO International Convention helps to support the association's programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of improving the world through biotechnology innovation.

BIO represents more than 1200 biotechnology companies, academic institutions, state biotechnology centers, and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. BIO also produces the annual BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held worldwide.


Related Links:
Biotechnology Industry Organization

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic Hematology Analyzer
DH-800 Series
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.